Immupharma PLC Share Subscription into Incanthera plc (3634A)

TIDMIMM TIDMINC

RNS Number : 3634A

Immupharma PLC

29 September 2020

ImmuPharma plc

("ImmuPharma" or the "Company")

Share Subscription into Incanthera plc

("Incanthera")

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that further to a subscription agreement entered into at the time of Incanthera's IPO onto AQSE Growth Market* in February 2020, ImmuPharma has now executed its subscription agreement to subscribe GBP250,000 for 2,631,579 ordinary shares of 2p each at a subscription price equal to Incanthera's IPO price of 9.5p each.

Following this subscription, ImmuPharma will hold 9,904,319 shares in Incanthera, representing a 15.35% position in the enlarged share capital of Incanthera.

ImmuPharma notes two recent positive announcements from Incanthera regarding studies of its lead product Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. These announcements can be viewed on Incanthera's website:

http://www.incanthera.com/news-media/news/2020/september/successful-results-of-permeation-study/

http://www.incanthera.com/news-media/news/2020/september/successful-results-of-sensitisation-study/

Commenting on the announcement, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer said:

"ImmuPharma is a strong supporter of Incanthera, sharing common goals of progressing both of our therapeutic pipelines to benefit the long term health of patients, globally.

We are extremely pleased to note Incanthera's two recent announcements, evidencing great progress towards its immediate goal of taking its lead product Sol to market."

*Formerly known as NEX Exchange Growth Market

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR").

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin 
 
    Stanford Capital Partners (Joint Broker)      +44 (0) 203 36 8 3550 
    Patrick Claridge 
    John Howes 
    Bob Pountney                                   +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer.

The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase III trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk .

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Incanthera plc

Incanthera (AQSE: INC), is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

For more information please visit: www.incanthera.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKKFBQFBKDBCB

(END) Dow Jones Newswires

September 29, 2020 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024